Discovering PARP inhibitor resistance with CRISPR

Discovering PARP inhibitor resistance with CRISPR

Ben Sidders - Head of Oncology Bioinformatics at AstraZeneca - Knowledge graphs for drug discoveryПодробнее

Ben Sidders - Head of Oncology Bioinformatics at AstraZeneca - Knowledge graphs for drug discovery

Highlighting the Power of CRISPRa/i for Gene Expression Profiling WebinarПодробнее

Highlighting the Power of CRISPRa/i for Gene Expression Profiling Webinar

CRISPR in Functional Genomics and Drug Discovery at World CRISPR Day 2020Подробнее

CRISPR in Functional Genomics and Drug Discovery at World CRISPR Day 2020

Mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2 mutated metastati...Подробнее

Mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2 mutated metastati...

Discovering PARP inhibitor resistance mechanisms using genome-wide and focused CRISPR screensПодробнее

Discovering PARP inhibitor resistance mechanisms using genome-wide and focused CRISPR screens

PARP Inhibitor Mechanisms of ResistanceПодробнее

PARP Inhibitor Mechanisms of Resistance

CRISPR-guided Therapeutic Discovery: First-in-Class Inhibitors of CHD4 for GlioblastomaПодробнее

CRISPR-guided Therapeutic Discovery: First-in-Class Inhibitors of CHD4 for Glioblastoma

Characterization of a PARP Inhibitor Biomarker for Cancer Therapy (AACR)Подробнее

Characterization of a PARP Inhibitor Biomarker for Cancer Therapy (AACR)

Combining CRISPR and AI to accelerate cancer drug discoveryПодробнее

Combining CRISPR and AI to accelerate cancer drug discovery

What is a PARP Inhibitor? | Dana-Farber Cancer Institute | Science IllustratedПодробнее

What is a PARP Inhibitor? | Dana-Farber Cancer Institute | Science Illustrated

Targeted cancer therapy: choosing the right assay to assess PARP inhibitorsПодробнее

Targeted cancer therapy: choosing the right assay to assess PARP inhibitors

Overcoming Resistance to PARP Inhibitors in Ovarian CancerПодробнее

Overcoming Resistance to PARP Inhibitors in Ovarian Cancer

Dr. Konecny on Resistance to PARP Inhibitors in Ovarian CancerПодробнее

Dr. Konecny on Resistance to PARP Inhibitors in Ovarian Cancer

Combinations May Combat PARP ResistanceПодробнее

Combinations May Combat PARP Resistance

Dr Patricia Roxburgh: Can resistance to PARP inhibitors be overcome in advanced ovarian cancers?Подробнее

Dr Patricia Roxburgh: Can resistance to PARP inhibitors be overcome in advanced ovarian cancers?

CRISPR/Cas9 screens: CRISPRko (knockout) vs. CRISPRi (interference)Подробнее

CRISPR/Cas9 screens: CRISPRko (knockout) vs. CRISPRi (interference)

OCA Symposium:Olga Kondrashova on resistance and sensitivity to PARP inhibition in ovarian cancerПодробнее

OCA Symposium:Olga Kondrashova on resistance and sensitivity to PARP inhibition in ovarian cancer

PARP-inhibitors: A New Generation of Cancer DrugsПодробнее

PARP-inhibitors: A New Generation of Cancer Drugs